분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2014-11-20 15:30:14 , Hit : 1159
 Gilead wins European approval of next-generation hepatitis C drug




Nov 18, 2014, 10:52am PST
  
John Martin of Gilead


Tony Avelar

John Martin of Gilead
    


          
Ron LeutyReporter-
San Francisco Business Times

Gilead Sciences Inc.'s next-generation hepatitis C drug won European approval Tuesday, opening the door for the drug to be sold in 28 countries.

Pricing of Harvoni, which has raised eyebrows at $95,000 in the United States, is a little more complex since the Foster City-based company (NASDAQ: GILD) must negotiate with individual countries.

Still, Wall Street viewed the approval by the European Commission positively, pushing the stock nearly 3 percent higher to $103.33 per share in mid-day trading, compared to Monday's close. The stock had fallen more than 10 percent this month, through Monday, due to concerns about insurers paying the hefty price.


See Also
Gilead seeks FDA approval for new HIV pill
Gilead's $1,000-a-pill hepatitis C drug may make financial sense for prisons

Harvoni — the first once-daily tablet targeting chronic hepatitis C — was approved last month by the Food and Drug Administration. It combines the drug ledipasvir with Sovaldi, Gilead's first-generation hepatitis C drug that was approved in the United States in December 2013 and in Europe in January 2014.

Gilead Chairman and CEO John Martin and other company executives have argued that three to four months of Harvoni and Sovaldi are valuable because they steer hepatitis C patients away from 48 weeks of injections of interferon and ribavirin, two drugs whose side effects are blamed for patients discontinuing therapy.

Chronic hepatitis C can lead to liver cancer and transplants, and Gilead officials have said that the high, short-term prices of Harvoni and Sovaldi in the United States are less than the longer-term prices of liver cancer drugs and transplantation.

European approval of Harvoni in hepatitis C patients with genotype 1 — the most prevalent form of the disease in Europe — and genotype 4 comes a week after Gilead said Harvoni had cure rates of 96 percent to 97 percent in a study of patients who had cirrhosis and hadn't benefitted from previous treatments.







987   인간과 생쥐 유전체의 유사성과 차이점  이성욱 2014/11/25 1923
986   Cost to Develop a Drug More Than Doubles to $2.56 Billion  이성욱 2014/11/21 1128
985   세균과 싸우도록 자극하면, 바이러스까지도 물리치는 세포  이성욱 2014/11/20 1492
  Gilead wins European approval of next-generation hepatitis C drug  이성욱 2014/11/20 1159
983   [바이오토픽] 표준 인간 게놈지도의 갭을 메워라: 플래티넘 게놈지도 탄생  이성욱 2014/11/19 1595
982   종양 내에서 T 세포 면역에 핵심적인 항원제시 세포  이성욱 2014/11/17 1659
981   AbbVie, Enanta drug shows potential in hep C genotype 4 patients  이성욱 2014/11/15 1187
980   Gilead hepatitis C drug highly effective in cirrhosis patients  이성욱 2014/11/14 1068
979   새로운 HIV/AIDS 치료법 개발  이성욱 2014/11/14 1468
978   간 이식 환자들의 C형 간염을 완치시킨 새로운 치료법  이성욱 2014/11/14 1665
977   간 이식 환자들의 C형 간염에 효과적인 병용 요법  이성욱 2014/11/13 1608
976   J&J Wins U.S. Approval for Hepatitis C Combo With Gilead  이성욱 2014/11/07 1523
975   에볼라에 대한 반응과 유전적 요인  이성욱 2014/11/04 1279
974   실험실에서 만든 인공위장  이성욱 2014/11/04 1222
973   거울이미지 RNA효소와 생명이 기원  이성욱 2014/11/03 1493
972   어떻게 복잡한 생명은 진화했는가?  이성욱 2014/10/31 1601
971   인간 녹아웃을 연구하는 유전학자들  이성욱 2014/10/31 1563
970   As the RNA World Turns (Either Way, with Cross-Chiral Enzyme)  이성욱 2014/10/31 1348
969   암의 우군-엑소좀(exosome)  이성욱 2014/10/29 2789
968   이웃의 정상세포를 감염시키는 암세포  이성욱 2014/10/27 1464

[이전 10개] [1]..[11][12][13][14] 15 [16][17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN